2018
MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC
Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Hernandez G, Foster P, Spahn J, O'Hear C, Gettinger S. MA15.02 Long-Term Safety and Clinical Activity Results from a Phase Ib Study of Erlotinib Plus Atezolizumab in Advanced NSCLC. Journal Of Thoracic Oncology 2018, 13: s407. DOI: 10.1016/j.jtho.2018.08.440.Peer-Reviewed Original ResearchSafety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK + advanced NSCLC (aNSCLC).
Kim D, Gadgeel S, Gettinger S, Riely G, Oxnard G, Mekhail T, Schmid P, Dowlati A, Heist R, Wozniak A, Hernandez G, Sarkar I, Mitry E, Foster P, O'Hear C, Spahn J, Ou S. Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK + advanced NSCLC (aNSCLC). Journal Of Clinical Oncology 2018, 36: 9009-9009. DOI: 10.1200/jco.2018.36.15_suppl.9009.Peer-Reviewed Original Research
2017
84O Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial
Peters S, Costa E, Garassino M, Christoph D, Kurata T, Chaft J, Johnson M, Mocci S, Gettinger S, Felip E. 84O Atezolizumab as first-line (1L) therapy for advanced non-small cell lung cancer (NSCLC) in PD-L1–selected patients: Efficacy data from the BIRCH trial. Annals Of Oncology 2017, 28: ii29-ii30. DOI: 10.1093/annonc/mdx091.004.Peer-Reviewed Original ResearchAtezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study
Eberhardt W, Garassino M, Rizvi N, Besse B, Jänne P, Peters S, Toh C, Kurata T, Costa E, Koczywas M, Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017, 71: s1-s125. DOI: 10.1055/s-0037-1598277.Peer-Reviewed Original ResearchOA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study
Garassino M, Rizvi N, Besse B, Jänne P, Christoph D, Peters S, Toh C, Kurata T, Costa E, Koczywas M, Felip E, Chaft J, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M. OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. Journal Of Thoracic Oncology 2017, 12: s251-s252. DOI: 10.1016/j.jtho.2016.11.239.Peer-Reviewed Original ResearchP3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT
Rudin C, Cervantes A, Dowlati A, Besse B, Ma B, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O'Hear C, Gettinger S. P3.02c-046 Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC Topic: IT. Journal Of Thoracic Oncology 2017, 12: s1302-s1303. DOI: 10.1016/j.jtho.2016.11.1841.Peer-Reviewed Original Research
2016
441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Ma B, Rudin C, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O'Hear C, Gettinger S, Besse B. 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Annals Of Oncology 2016, 27 DOI: 10.1093/annonc/mdw594.005.Peer-Reviewed Original Research441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC
Ma B, Rudin C, Cervantes A, Dowlati A, Costa D, Schmid P, Heist R, Villaflor V, Sarkar I, Huseni M, Foster P, O’Hear C, Gettinger S, Besse B. 441O Preliminary safety and clinical activity of erlotinib plus atezolizumab from a Phase Ib study in advanced NSCLC. Annals Of Oncology 2016, 27: ix141. DOI: 10.1016/s0923-7534(21)00599-8.Peer-Reviewed Original ResearchORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results Topic: Medical Oncology
Wakelee H, Patel J, Heist R, Balmanoukian A, Besse B, Felip E, Costa E, Chow L, Koczywas M, Garassino M, Christoph D, Toh C, Johnson M, Chaft J, Kurata T, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Peters S. ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1–Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results Topic: Medical Oncology. Journal Of Thoracic Oncology 2016, 11: s251-s252. DOI: 10.1016/j.jtho.2016.09.009.Peer-Reviewed Original Research
2015
513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study
Giaccone G, Camidge D, Liu S, Powderly J, Hodi F, Gettinger S, Heist R, Liu B, Wallin J, Funke R, Waterkamp D, Ready N. 513 Safety, activity and biomarkers of atezolizumab (MPDL3280A) with platinum-based chemotherapy (chemo) in non-small cell lung cancer (NSCLC): A Phase Ib study. European Journal Of Cancer 2015, 51: s107-s108. DOI: 10.1016/s0959-8049(16)30314-8.Peer-Reviewed Original Research